Home
    Abstracts
    Registration
    Accommodation
    Webcasting
     Home
     Welcome Note
     Committees
     Faculty
     Time Table
     Scientific Program
     Poster Presentations
         Guided Poster Tours
         Poster Presentation Guidelines
         Best Abstract Prize
         Best Poster Prize
     Registration
         Czech and Slovak Participants
     Accompanying Persons Program
     Accommodation
     Sponsorship & Exhibition
     Sponsors
     CME
     CONy Feedback Form
     Last Useful Information!
     General Information
         Official Airline Network
     About Prague
         Transportation
         Tips & Hints
     Invitation Letter
     Past & Future CONy Congresses
     CONy 2008 Webcasting
     Media Partners & Links
     Contact Us
The 3rd World Congress on
Controversies in Neurology (CONy)
Clarion Congress Hotel, Prague, Czech Republic, October 8-11, 2009
 
  Scientific Program Print
PLENARY SESSION & OPENING CEREMONY
 
Thursday, October 8, 2009
Chairpersons:
A.D. Korczyn, Israel; I. Rektor, Czech Republic; D. Muresanu, Romania
17:00-17:20
Greetings
17:20-17:40
C. Hoschl, Czech Republic
17:40-18:00
R. Bondy, Israel
18:00-19:00
Capsule:
Debate: The role of evidence-based medicine (EBM)
EBM has developed into a state-of-the-art way to evaulate new drugs. Does it really provide the promise?
19:00
Welcome Reception
 
 
MULTIPLE SCLEROSIS

Friday, October 9, 2009
07:30-08:30
GUIDED POSTER TOUR #1
Session 1
MS: NEW THERAPIES
08:30-10:30
Capsule:
Pseudobulbar affect (PBA) is an important clinical feature of several neurological diseases, including MS. Its pathogenesis and treatment will be discussed, as well as the role of new therapies.
Chairpersons:
E. Havrdova, Czech Republic; Z. Szolnoki, Hungary
08:30-09:30
Debate: Emotional lability and pseudobulbar affect (PBA) in MS
Sponsored by an unrestricted grant from Avanir Pharmaceuticals
Commentator: A. Miller, Israel
09:30-10:30
Debate: Newly emerging therapies: Do their potential benefits outweigh the risks?
Sponsored by an unrestricted grant from Teva - Sanofi Aventis
Yes: R. Milo , Israel
No: O. Stuve , USA
Commentator: P. Vermersch, France
10:30-11:00
Coffee Break
Session 2
CLINICAL MANAGEMENT OF MS
11:00-13:00
Capsule:
The availability of MRI allows clinicians to differentiate various presentations. This is particularly true of clinically isolated syndrome (CIS). However, are all CIS caes to be regarded in the same way? And once treatment is initiated, what is the proper method?
Chairpersons:
J. Losy, Poland; A. Miller, USA
11:00-12:00
Debate: CSF examination is mandatory in every CIS case, regardless of MRI findings
Pro: C. Confavreux, France
Con: E. Havrdova, Czech Republic
Commentator: A. Siva, Turkey
12:00-13:00
Debate: Escalation therapy vs. induction therapy
Escalation: X. Montalban, Spain
Induction: G. Comi, Italy
Commentator: N. Putzki, Germany
13:00-14:00
Lunch Break
Session 3
MS: PREVENTION AND TREATMENT
14:00-16:00
Capsule:
In spite of the fact that the etiology of MS is still unknown, data is accumulating, suggesting metabolic changes such as in vitamin D, or viral infections as causes. This suggests potential neuroprotective therapies. On the other extreme, new therapies have developed, which also have significant toxicity, posing questions on how and when these should be used.
Chairpersons:
A.N. Boyko, Russia; Z. Stelmasiak, Poland
14:00-15:00
Debate: Can we prevent MS with early life Vitamin D supplementation and EBV vaccination?
Yes: A. Chaudhuri, UK
No: J. Chapman, Israel
Commentator: I. Steiner, Israel
15:00-16:00
Debate: Do natalizumab's benefits outweigh the risks?
Efficacy is so good we should use it frequently: N. Putzki, Switzerland
Side effects are too significant: G. Comi, Italy
Commentator: H.-P. Hartung, Germany
16:00-16:30
Coffee Break
Session 4
NEW PLAYERS IN MS
16:30-18:00
Capsule:
Several new drugs are in different stages of development against MS. The up-to-date status of the main ones will be discussed.
Chairpersons:
J. Chapman, Israel; G. Comi, Italy
Cladribine: P. Vermersch, France
Laquinimod: A.N. Boyko, Russia
Alemtuzumab: J. Losy, Poland
Rituximab: N. Putzki, Germany
Fumarate: E. Havrdova, Czech Republic
Fingolimod: H.P. Hartung, Germany
A. Siva, Turkey

STROKE
Friday, October 9, 2009
07:30-08:30
GUIDED POSTERS TOUR #1
Session 5
STROKE PREVENTION
08:30-10:30
Capsule:
Carotid stenosis is one of the major causes of ischemic stroke. Interpretation of the results of the RCTs on the management of asymptomatic carotid stenosis is still controversial.
Chairpersons:
P. Kalvach, Czech Republic; Z. Trkanjec, Croatia
08:30-09:30
Debate: Asymptomatic carotid stenosis: Intervention of just stick to medical therapy?
Sponsored by an unrestricted grant from Abbott Vascular
To operate: A. Halliday, UK
To stent: G. Chrysant, USA
Medical therapy: J. Streifler, Israel
Commentator: J. Wojczal, Poland
09:30-10:30
Debate: Should mechanical embolectomy devices be used in routine clinical practice?
Yes: M. Bar, Czech Republic
No: P. Sandercock, UK
Commentator: C. Molina, Spain
10:30-11:00
Coffee Break
Session 6
INTRACRANIAL BLEEDING
10:30-11:00
Capsule:
Microbleeds (MB) are detectable on routine MRI studies and may indicate high risk of bleeding. However, it is still unclear whether MB on MRI should guide our antithrombotic therapy. The treatment of subarachnoid hemorrhage has also undergone changes in the past decade, with the development of new technological approaches.
Chairpersons:
E. Ehler, Czech Republic; R. Rangel-Guerra, Mexico
11:00-12:00
Debate: Be careful of CAA and microbleedings when giving anti-thrombosis treatment
Pro: W.W. Zhang, China
Con: C. Cordonnier, France
Commentator: D. Russell, Norway
12:00-13:00
Debate: Treatment of aneurysmal subarachnoid hemorrhage
 
Coiling: O. Bajenaru, Romania
Clipping: S. Florian, Romania
Commentator: J. van Gijn, The Netherlands
13:00-14:00
Lunch Break
Session 7
STROKE TREATMENT
14:00-16:00
Capsule:
The recent ECAS-III trial's result rasied a lot of controversies on whether the therapeutic window should be extended to 4.5 hours. The results of the statins trials (HPS & SPARC L, etc) raised the quesiton on whether statins should be given following all ischemic strokes, regardless of lipid profile, for second stroke prevention.
Chairpersons:
A. Halliday, UK; S. Klimosova, Czech Republic
14:00-15:00
Debate: IV tPA beyond 3 hours: Is it suitable for everyone?
Yes: P. Schellinger, Germany
No: P. Sandercock, UK
Commentator: C. Cordonnier, France
15:00-16:00
Debate: Statins should be given to every stroke patient for secondary stroke prevention
Yes: D. Russell, Norway
No: J. van Gijn, The Netherlands
Commentator: P. Sandercock, UK
16:00-16:30
Coffee Break
Session 8
NEW TREATMENTS IN STROKE
16:30-18:30
Capsule:
Although there has been a substantial progress in the treatment of stroke, in many areas there is still a long way to go. New innovative and exciting approaches for stroke therapy are currently under investigation.
Chairpersons:
D. Bartko, Slovakia; R. Mikulik, Czech Republic
16:30-17:30
Debate: Do animal models fail us in finding new treatments for stroke?
Commentator: P. Sandercock, UK
17:30-18:30
NEW PLAYERS IN STROKE
 
CoAxia: P. Schellinger, Germany
IMPACT 24: D. Krieger, Denmark
Sonothrombolysis: C. Molina, Spain
Citicoline: E. Diez-Tejedor, Spain
Albumin: M. Ginsbe rg, USA
Cerebrolysin: D. Muresanu, Romania
Medical embolectomy: M. Abelson, South Africa

PARKINSON'S DISEASE

Friday, October 9, 2009
07:30-08:30 GUIDED POSTER TOUR #1
Session 9 TRADITIONAL VS MODERN THERAPY
08:30-10:30
Capsule:
L-dopa has been established as the gold standard of PD therapy; but older azotheric therapies are still being used extensively. The timing of initation of drug therapy is still debated.
Chairpersons:
E. Martignoni, Italy; J. Roth, Czech Republic
08:30-09:30
Debate: Ayurveda medicine is efficacious therapy in PD
Pro: H. Przuntek, Germany
Con: O. Rascol, France
Commentator: A. Kupsch, Germany
09:30-10:30
Debate: The earlier the better: Treatment should be started immediately on diagnosis
Pro: A.H.V. Schapira, UK
Con: C.E. Clarke, UK
Commentator: E. Ruzicka, Czech Republic
10:30-11:00 Coffee Break
Session 10
MODERN THERAPY IN PD: EARLY AND LATE TREATMENT STRATEGIES IN PD
Sponsored by an unrestricted grant from Solvay Pharmaceuticals
11:00-13:00
Capsule:
Early and late treatment strategies in PD are still a cause of disagreement. What are the advantages of each?
Chairpersons:
M. Bares, Czech Republic; C. Falup, Romania
11:00-12:00
Debate: What is the best drug for early PD patients?
MAO-B-inhibitor: H. Reichmann, Germany
Dopamine agonist: O. Rascol, France
Levodopa: E. Ruzicka, Czech Republic
Commentator: L. Vecsei, Hungary
12:00-13:00
Debate: What is the best treatment for advanced fluctuating PD
Duodopa: P. Odin, Germany
Apomorphine: R. Hilker, Germany
DBS: E. Seigneuret, France
Commentator: A. Antonini, Italy
13:00-14:00 Lunch Break
Session 11 PATHOPHYSIOLOGY OF PD
14:00-16:00
Capsule:
Linkage of new diagnostic procedures and pathophysiological aspects: Can they help us better understand PD pathogenesis?
Chairpersons:
I. Rektor, Czech Republic; E. Sidransky, USA
14:00-15:00 Debate: Substantia nigra hyperecogenicity is a risk marker of PD
Yes: D. Berg, Germany
No: U. Walter, Germany
Commentator: TBA
15:00-16:00
Debate: Does PD have a prion-like pathogenesis?
Yes: R. Hilker, Germany
No: J. Chapman, Israel
Commentator: J. Brotchie, Canada
16:00-16:30 Coffee Break
Session 12 COGNITIVE IMPAIRMENT IN PD
16:30-18:30
Capsule:
New findings may sometimes be old. From dementia to long-term modulations in PD
Chairpersons:
Z. Pirtosek, Slovenia; D. Truong, USA
16:30-17:30
Debate: MCI in PD?
MCI exists in PD: I. Rektorova, Czech Republic
MCI is not a useful concept in PD: J. Kulisevsky, Spain
Commentator: A. Szczudik, Poland
17:30-18:30 NEW PLAYERS IN PD
Ropinirole prolonged release: E. Ruzicka, Czech Republic
Lisuride Patch: R. Horowski, Germany
Safinamide: A.V.H. Schapira, UK
PYM50028 (COGANE ): J. Brotchie, Canada

EPILEPSY
 
Saturday , October 10, 2009
07:30-08:30 GUIDED POSTERS TOUR #2
Session 13 NEUROSURGICAL CONDITIONS
08:30-10:30
Capsule:
This section revies two longs regarding the treatment of seizures. The first debate pertains to the need for prophylactic antiepileptic drug therapy for patients with brain tumors. It is well established that some patients with tumors develop seizures. What is the role of drug therapy before seizures develop? Does it reduce the chance of developing seizures, mitigate the adverse effects of seizures or does it constitute unnecessary hterapy, with the potential for side effects exceeding the potential for benefit? The second topic relates to surgical therapy for epilepsy. Success rates are best when an epileptogenic structural lesion is excised, and are considerably lower when a structural lesion cannot be identified. Should surgery be offered to patients with no evidence for a structural lesion, or be restricted to those who have a high probability of success?
Chairpersons:
M. Brazdil, Czech Republic; M. Levite, Israel
08:30-09:30 Debate: Should prophylactic antiepileptic therapy be prescribed to patients with brain tumors?
Yes: T. Tomson, Sweden
No: E. Beghi, Italy
Commentator: M. Brodie, UK
09:30-10:30 Debate: Should surgery be offered to patients with extra-temporal epilepsy (frontal, parietal, occipital) if the MRI does not show a structural lesion?
Yes: M. Neufeld, Israel
No: M. Sperling, USA
Commentator: I. Rektor, Czech Republic
10:30-11:00 Coffee Break
Session 14 MEDICAL TREATMENT OF EPILEPSY
11:00-13:00
Capsule:
Seizures are associated with morbidity, and occasionally, mortality. Medications also are associated with side effects. Is it reasonable to stop antiepileptic medication in a well-controlled patient, knowing that a significant proportion of patients may have a recurrent seizure with its attendant risks? The first debate will reveiw the pros and cons of continuing or stopping medical therapy in well-controlled patients with epilepsy. The second debate addresses the timely issue of use of valporate in women of child bearing age with idiopathic generalized epilepsy. Valproate has been associated with birth defects and cognitive impairment in offspring of women taking that drug while pregnant, yet it is often the agent with the best chance of prodcuing seizure control in many of the idopathic generalized epilepsies. Are there circumstances in which it should be used, and are there ways of using it that minimize its risk?
Chairpersons:
R. Kuba, Czech Republic; W. Theodore, USA
11:00-12:00 Debate: Is AED discontinuation in seizure-free patients dangerous?
Yes: D. Schmidt, Germany
No: E. Beghi, Italy
Commentator: A. Guekht, Russia
12:00-13:00 Debate: Should valproate be prescribed to women of childbearing age with idiopathic generalized epilepsy?
Yes: T. Tomson, Sweden
No: A. Guekht, Russia
Commentator: M. Brodie, UK
13:00-14:00 Lunch Break
Session 15 NEW PLAYERS IN EPILEPSY
14:00-16:00
Capsule:
Many individuals with epilepsy continue to experience seizures despite appropriate medical therapy. The first talk will review mechanisms of drug resistance. In response to the lack of adequate response, a new generation of antiepileptic medications is being developed. This session will review some new agents either recently approved or in the pharmaceutical pipeline.
Chairpersons:
P. Mares, Czech Republic; K. Rejdak, Poland
14:00-14:30
Lecture: Mechanisms of drug resistance
M. Brodie , UK
Chairpersons:
A. Guekht, Russa; I. Rektor, Czech Republic
14:30-16:00
Lacosamide: D. Schmidt, Germany
Rufinamide: V. Komarek, Czech Republic
Retigabine: M. Brodie, UK
Brivaracetam: M. Brazdil, Czech Republic
Carisbamate: B. Chmielewska, Poland
Perampanel: M. Sperling, USA
Pregabalin: V. Donath, Slovakia
16:00-16:30 Coffee Break
Session 16 EPILEPSY STUDY CASES
16:30-18:00
Capsule:
This session will be devoted to discussion of ordinary and difficult cases of epilepsy. A distinguished panel will dicuss issues related to diagnosis and management of seizure disorders.
Presenter: M. Sperling, USA
Panel:
E. Beghi
, Italy
M. Brodie, UK
S. J. Czuczwar, Poland
A. Guekht, Russia
M. Neufeld, Israel
I. Rektor, Czech Republic

D. Schmidt, Germany
W. Theodore, USA
PAIN AND HEADACHE
 
 
Saturday , October 10, 2009
 
 
07:30-08:30
GUIDED POSTERS TOUR #2
Session 17
LATEST ADVANCES IN MIGRAINE RESEARCH AND TREATMENTS
Sponsored by an unrestricted grant from Merck & Co., Inc
08:30-10:30
Capsule:
While migrainous headaches are common and disabling, their pathogenesis and nosology are still unclear. Migraine has a clear genetic background yet it has proven very difficult to pinpoint the genes involved. The clinical manifestations vary considerably within attacks and across patients. This session debates over de role of various neurotransmitters and neuromediators which are involved in the pathophysiology of migraine, such as CGRP receptor antagonists, their effectiveness, safety and tolerability in acute migraine.
The session also presents the most recent data on the genetics of migraine and its implications for novel treatments.
Chairpersons:
H. Bolay, Turkey; R. Hering, Israel
08:30-09:00
09:00-09:30
09:30-10:00
10:00-10:15
10:15-10:30
Unmasking headache myths
M. Ferrari, The Netherands; A. Rapoport, USA
L. Griffiths, Australia
A. Rapoport, USA
T. Ho, USA
Discussion
10:30-11:00
Coffee Break
 
 
Session 18
HEADACHE THERAPY
11:00-13:00
Capsule:
Triptans work well, but what is the optimal time to take them? Vitamins may help migraine, but do they decrease disability?
Chairpersons:
M. Kapisyzi, Albania; O. Keller, Czech Republic
11:00-12:00
Debate: Patients with medication overuse headache should undergo withdrawal prior to initiating preventative medication
Pro: N. Mathew, USA
Con: J. Schoenen, Belgium
Commentator: A. Rapoport, USA
 
 
12:00-13:00
Debate: Vitamin supplementation affects migraine disability
Pro: L. Griffiths, Australia
Con: A. Mauskop, USA
Commentator: J. Schoenen, Belgium
13:00-14:00
Lunch Break
Session 19
MIGRAINE TREATMENT AND PATHOPHYSIOLOGY
14:00-16:00
Capsule:
What are the nuances of treating medication overuse in headache and where does migriane begin? In the brain or outside it?
Chairpersons:
L. Griffiths, Australia; A. Mauskop, USA
14:00-15:00
Triptans must be given early when the headache is mild for them to work well
Pro: D . Mitsikostas, Greece
Con: J. Schoenen, Belgium
Commentator: N. Mathew, USA
15:00-16:00
16:00-16:30
Coffee Break
Session 20
IVIG: THE NEW INDICATIONS ON THE BLOCK
Sponsored by an unrestricted grant from Baxter Healthcare
16:30-18:30
Capsule:
Should chronic inflammatory polyneuropathy (CIDP) be treated with IVIG? Should Alzhiemer's disease be treated with IVIG?
Chairpersons:
E. Nobile-Orazio, Italy; L. Spiru, Romania
16:30-17:30
Debate: AD can be treated by IVIG
Pro: N. Relkin, USA
Con: R. Rusina, Czech Republic
Commentator: U. Bonnucelli, Italy
17:30-18:30
Debate: CIDP can be treated permanently with IVIG
Pro: H.-P. Hartung, Germany
Con: I. Wirguin, Israel
Commentator: P. Kennedy, UK
 
 
ALZHEIMER'S DISEASE/DEMENTIA & INFECTIOUS DISEASES
 
Saturday , October 10, 2009
07:30-08:30
GUIDED POSTERS TOUR #2
Session 21
DEMENTIA: CAUSES AND DIAGNOSIS
08:30-10:30
Capsule:
The theories designed to understand the pathogenesis of Alzheimer's disease (AD) are still incomplete. Has an infectious etiology been ruled out? Dementia with Lewy bodies is frequently associated with Parkinsonian symptoms. Can imaging help in early diagnosis?
Chairperson:
U. Bonnucelli, Italy; J. Hort, Czech Republic
08:30-09:30
Debate: AD: Are we intervening too late?
Yes: V.-O. Emery, USA
No: D. Ames, Australia
Commentator: B.O. Popescu, Romania
09:30-10:30
Debate: Infectious agents: A cause of AD?
Pro: R. Itzhaki, UK
Con: A. Chaudhuri, UK
Commentator: E. Havrdova, Czech Republic
10:30-11:00
Coffee Break
Session 22
TREATMENT OF AD
11:00-13:00
Capsule:
Treatment of AD is still not very efficacious. Is it because we do not understand the mechanisms, are the studies not properly designed, or is the timing of intervention wrong?
Chairpersons:
R. Rusina, Czech Republic; M. Windisch, Austria
11:00-12:00
Debate: Why so few new drugs on the market for AD therapy? Is the target the problem or the clinical trails?
The clinical trials are wrong: J. Hort, Czech Republic
The target is wrong: E. Giacobini, Switzerland
Commentator: D. Ames, Australia
12:00-13:00
Debate: Is SPECT imaging critical to diagnose dementia with Lewy bodies?
Yes: Z. Walker, UK
No: M. Bojar, Czech Republic
Commentator: J. Kulisevsky, Spain
13:00-14:00
Lunch Break
Session 23
CONTROVERSIES IN NEUROREHABILITATION
Sponsored by an unrestricted grant from The Society for the Study of Neuroprotection and Neuroplasticity
14:00-16:00
Capsule:
Neurorehabilitation is our precious effort towards recovery. It is still unclear how we will get the best of our clinical endeavors. Also, we still have to decide if we listen to intelligent molecules wisdom or to fascinating new technologies or even combine them sometimes.
Chairpersons:
D. Muresanu, Romania; O. Svestkova, Czech Republic
14:00-15:00
Debate: In-patients vs. out-patients neurorehabilitation: Profit and outcome
J.-L. Truelle, France
Commentator: K. von Wild, Germany
15:00-16:00
Debate: Neuromodulation in restorative neurology: Deep brain stimulation (DBS) vs. pharmacological treatment in neurorecovery
DBS for neurorecovery: M. Mehdorn, Germany
Commentator: K. von Wild, Germany
16:00-16:30
Coffee Break
Session 24
INFECTIONS
16:30-18:30
Capsule:
In many neurological disorders where the etiology and pathogenesis are unknown, a possible infectious etiology has been proposed and is associated with therapeutic dilemmas. Infections of the nervous system, per se, pose diagnostic and therapeutic challenges. This session focuses on two issues in neurological infections that confront practicing neurologist and have important clinical implications.
Chairpersons:
B.O. Popescu, Romania; G. Ransmayr, Austria
16:30-17:30
Debate: HSV-1 as the causative agent in Bell's palsy
Pro: I. Wirguin, Israel
Con: P. Kennedy, UK
Commentator: I. Steiner, Israel
17:30-18:30
Debate: Treatment of bacterial meningitis: Empiric antibiotics or lumbar puncture: Which should be the first step?
Commentator: TBA
 

ALZHEIMER'S DISEASE/DEMENTIA & INFECTIOUS DISEASES
Sunday , October 11, 2009
 
Session 25
NEUROPLASTICITY WITH THE GOODS AND THE BADS, FROM CLASSIC TO QUANTUM APPROACH
08:30-10:30
Capsule:
Neuroplasticity is one of the powerful and harmonious realities of the brain aiming to maintain, adapt and regenerate neuronal circuitry. This amazing process is governed by molecular mechanisms but also by a complex mind-brain interface. Sometimes, faulty mechanisms might disturb the harmony.
Chairpersons:
B. El-Ad, Israel; K. von Wild, Germany
08:30-08:50
08:50-09:10
09:10-09:30
09:30-09:50
09:50-10:10
10:10-10:20
10:20-10:30
J. Schwartz, USA
D. Muresanu, Romania
O. Bajenaru, Romania
B.O. Popescu, Romania
Developing the next generation of treatment in AD
J. Bell, USA
Discussion
10:30-11:00
Coffee Break
Session 26
NEUROLOGICAL DISEASES: FROM PATHOGENESIS TO MODERN THERAPY
11:00-13:00
Capsule:
The need to find noval therapies for neurological disease is hampered by poor understanding of underlying mechanisms and the adverse events associated with the more potent new drugs.
Chairpersons:
O. Bajenaru, Romania; R. Itzhaki, UK
11:00-11:15
11:15-11:30
G. Vithoulkas, Greece
11:30-11:45
D. Blumenthal, Israel
11:45-12:00
12:00-13:00
Debate: Temperature and barometric pressure are the most significant conditions for triggering migraine headache
Pro: A. Rapoport, USA
Con: H. Bolay, Turkey
Commentator: L. Griffiths, Australia
13:00-13:30
POSTER AWARDS AND CLOSING CEREMONY
 
 
Sunday , October 11, 2009
 
Session 27 AD/PD BIOMARKERS
08:30-10:30
Capsule:
The diagnosis of neurological disorders is severely hampered by the absence of reliable biomarkers. This session presents and compares currently known / clinically applied biomarkers in neurological disorders which can be identified and incorporated into clinical drug trials and elucidate proposed mechanisms of disease and drug action.
Chairpersons:
R. Ravid, The Netherlands; B. Solomon, Israel
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00
10:00-10:15
10:15-10:30
E. Nordhoff, Germany
K. Marcus, Germany
D. Woitalla, Germany
G. Feuerstein, USA
H. Soares, USA
M. Memo, Italy
R. Ravid, The Netherlands
10:30-11:00 Coffee Break
Session 28 AD: WHAT IS THE ENTITY AND CAN IT EVERY BE CURED?
11:00-13:00
Capsule:
While the term AD is commonly used, there are difficulties in its definition. Attempts to treat patients with this form of dementia have so far failed. Is there hope?
Chairperson:
E. Giacobini, Switzerland; I. Rektorova, Czech Republic
11:00-12:00
Debate: Confirming the diagnosis of early AD/MCI with biomarkers is clinically useful
Yes: L. Spiru, Romania
No: P.J. Visser, The Netherlands
Commentator: G. Ransmayr, Austria
 
12:00-12:30
F.C.C. Peng, Taiwan
12:30-12:40
P. Giannakopoulos, Greece
12:40-12:50
12:50-13:00 QEEG-neurometric analysis guided neurofeedback treatment in dementia: 9 cases "How neurometric analysis is important for the treatment of dementia as well as diagnosis?"
T. Surmeli, Turkey
13:00-13:30 POSTER AWARDS AND CLOSING CEREMONY
Chairpersons: A.D. Korczyn, Israel; I. Rektor, Czech Republic

Home   
Copyright © 2007 comtecmed.com. All rights reserved. Created by     WebStudio.co.il